Zeb1-mediated control of the PUFA/MUFA ratio in EMT-associated ferroptosis sensitivity
Zeb1-mediated control of the PUFA/MUFA ratio in EMT-associated ferroptosis sensitivity
批准号:
461704629
负责人:
Professor Dr. Thomas Brabletz
金额:
$0.0万
依托单位国家:
德国
项目类别:
Priority Programmes
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Ferroptosis is a highly conserved cell death pathway, depending on an iron and oxygen-radical mediated peroxidation of phospholipids. Importantly, such phospholipids need to be composed of certain species of polyunsaturated fatty acids (PUFAs). In contrast to apoptosis, the prominent death pathway in differentiated cells (e.g. epithelial cells), ferroptosis can be executed predominantly in undifferentiated cells and cells with a (partial) mesenchymal phenotype. In cancer cells this phenotype is often acquired by activation of the epithelial-mesenchymal transition (EMT) program, and associated with high metastatic competence and therapy-resistance. We could demonstrate that the EMT-activating transcription factor Zeb1 strongly increases PUFA-levels, whereas it decreases the counteracting monounsaturated fatty acids (MUFAs). We will proof if Zeb1 directly regulates the expression of the rate-limiting enzymes for PUFA- vs. MUFA-synthesis, i.e. downregulates expression of stearyl Co-A desaturase 1 (SCD1), which is critical for MUFA synthesis, and upregulates expression of fatty acid desaturase 2 (FADS2) and elongation of very long chain fatty acid 5 (ELOVL5), both rate-limiting enzymes for PUFA synthesis. We will further proof if altered expression and function of these enzymes accounts for the Zeb1-associated ferroptosis sensitivity in cancer cells with a (partial) mesenchymal phenotype. Finally, we will test if specific modulators of their expression and function will support ferroptosis activation as therapeutic strategy against highly aggressive cancer types.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of the EMT-inducer Zeb1 in the invasive tumor stroma during colon cancer progression
-
批准号:428418430
-
项目类别:Research Units
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
Cancer promoting transcriptional enhancers controlled by the EMT-activator ZEB1
-
批准号:416775465
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
The role of the EMT-inducer Zeb1 in the invasive tumor stroma during colon cancer progression
-
批准号:319467242
-
项目类别:Research Units
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
Interaction of the EMT-activator ZEB1 and the Yap/Taz/Hippo-pathway in cancer
-
批准号:314375996
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
Die Rolle der microRNA-200 Familie in der Tumorinvasion und Metastasierung
-
批准号:141068090
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
Die Rolle des EMT-Aktivators ZEB1 bei Verlust von Zellpolarität und Akkumulation von Tumorstammzellen in kolorektalen Karzinomen
-
批准号:64672955
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2008
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
The role of the oncoprotein ß-Catenin for invasion and metastasis formation of colorectal carcinomas
-
批准号:5368198
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2002
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
Targeting the roots of cancer metastasis and therapy resistance
-
批准号:511711508
-
项目类别:Reinhart Koselleck Projects
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Professor Dr. Thomas Brabletz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
基于NLRP3/IL-1β信号探讨α7nAChR介导巨噬细胞—心肌细胞互作在Aβ诱导房颤心房重构中的作用及机制研究
-
批准号:82300356
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:赵继凯
-
依托单位:
Tom1L1在胞内体蛋白分选机制中功能的研究
-
批准号:31171289
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2011
-
负责人:刘宁生
-
依托单位:
溶酶体依赖性TRAF2降解的机制
-
批准号:30971501
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2009
-
负责人:李联运
-
依托单位: